Notes
The SWITCH trials and the cost-effectiveness analysis were supported by Novo Nordisk.
Reference
Evans M, et al. Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy 9: 1919-1930, No. 5, Oct 2018. Available from: URL: http://doi.org/10.1007/s13300-018-0478-1
Rights and permissions
About this article
Cite this article
Insulin degludec: better outcomes, acceptable cost in T1DM and T2DM. PharmacoEcon Outcomes News 815, 20 (2018). https://doi.org/10.1007/s40274-018-5401-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5401-5